公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2011 | Nitrophenylboronic acids as highly chemoselective probes to detect hydrogen peroxide in foods and agricultural products | Lu, C.-P.; Lin, C.-T.; Chang, C.-M.; Wu, S.-H.; LEE-CHIANG LO | Journal of Agricultural and Food Chemistry | | 69 | |
2010 | Nitroreductase-mediated Gonadal Dysgenesis for Infertility Control of Genetically Modified Zebrafish | Hu, Shao-Yang; Lin, Pei-Yu; Liao, Chia-Hsuan; Gong, Hong-Yi; Lin, Gen-Hwa; Kawakami, Koichi; Wu, Jen-Leih | Marine Biotechnology | 28 | 25 | |
1983 | Nitrous Oxide in the Sea Off Southern California | 劉康克; Kaplan, I. R.; Liu, Kon-Kee | The Environment of the Deep Sea | | | |
1996 | Nitrous Oxide or Halothane, or Both, Fail to Suppress C-Fos Expression in Rat Spinal Cord Dorsal Horn Neurones after Subcutaneous Formalin | SUN, WEI-ZEN; HSIEH, CHANG-YAO | BRITISH JOURNAL OF ANAESTHESIA | | | |
1996 | Nitrous oxide or halothane, or both, fail to suppress c-fos expression in rat spinal cord dorsal horn neurones after subcutaneous formalin | WEI-ZEN SUN ; Shyu, B.C.; Shieh, J.Y. | British Journal of Anaesthesia | | | |
2003 | Nitrous oxide suppresses tonic and phasic nociceptive behaviors but not formalin-induced c-Fos expression in the rat spinal cord dorsal horn | FENG-SHENG LIN ; Shyu, B.-C.; Shieh, J.-Y.; WEI-ZEN SUN | Acta Anaesthesiologica Sinica | | | |
1993 | Nitroxyl Free Radical Enhancement of the Forbidden O2[3Σg-]←O2(1Δg) Radiative Transition in Chlorinated Hydrocarbon Solvents | Belford, R. E.; Seely, G.; Gust, D.; Moore, T. A.; Moore, A.; Cherepy, N. J.; Ekbundit, S.; Lewis, J. E.; 林聖賢; Lin, Sheng-Hsien | Journal of Photochemistry. Photobiology | | | |
2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | Doki, Yuichiro; Ajani, Jaffer A; Kato, Ken; Xu, Jianming; Wyrwicz, Lucjan; Motoyama, Satoru; Ogata, Takashi; Kawakami, Hisato; CHIH-HUNG HSU ; Adenis, Antoine; El Hajbi, Farid; Di Bartolomeo, Maria; Braghiroli, Maria I; Holtved, Eva; Ostoich, Sandra A; Kim, Hye R; Ueno, Masaki; Mansoor, Wasat; Yang, Wen-Chi; Liu, Tianshu; Bridgewater, John; Makino, Tomoki; Xynos, Ioannis; Liu, Xuan; Lei, Ming; Kondo, Kaoru; Patel, Apurva; Gricar, Joseph; Chau, Ian; Kitagawa, Yuko | The New England journal of medicine | 404 | 302 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 171 | 154 | |
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1666 | 1458 | |
2017 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. | The Lancet | 3010 | 2816 | |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 50 | 43 | |
2024 | Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 | El-Khoueiry, A B; Trojan, J; Meyer, T; Yau, T; Melero, I; Kudo, M; CHIUN HSU ; Kim, T-Y; Choo, S-P; Kang, Y-K; Yeo, W; Chopra, A; Soleymani, S; Yao, J; Neely, J; Tschaika, M; Welling, T H; Sangro, B | Annals of oncology : official journal of the European Society for Medical Oncology | 1 | | |
2020 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | Chen Y.-M.; CHIH-HSIN YANG ; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO ; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU | Journal of the Formosan Medical Association | 8 | 5 | |
2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 735 | 630 | |
2022 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial | Yau, Thomas; Park, Joong-Won; Finn, Richard S; ANN-LII CHENG ; Mathurin, Philippe; Edeline, Julien; Kudo, Masatoshi; Harding, James J; Merle, Philippe; Rosmorduc, Olivier; Wyrwicz, Lucjan; Schott, Eckart; Choo, Su Pin; Kelley, Robin Kate; Sieghart, Wolfgang; Assenat, Eric; Zaucha, Renata; Furuse, Junji; Abou-Alfa, Ghassan K; El-Khoueiry, Anthony B; Melero, Ignacio; Begic, Damir; Chen, Gong; Neely, Jaclyn; Wisniewski, Tami; Tschaika, Marina; Sangro, Bruno | The Lancet. Oncology | 510 | 433 | |
2021 | Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer | Sugawara, S; Lee, J-S; Kang, J-H; Kim, H R; Inui, N; Hida, T; Lee, K H; Yoshida, T; Tanaka, H; Yang, C-T; Nishio, M; Ohe, Y; Tamura, T; Yamamoto, N; CHONG-JEN YU ; Akamatsu, H; Namba, Y; Sumiyoshi, N; Nakagawa, K | Annals of oncology : official journal of the European Society for Medical Oncology | 96 | 73 | |
2021 | NK cell receptor and ligand composition influences the clearance of SARS-CoV-2 | Hsieh, Wan-Chen; Lai, En-Yu; Liu, Yu-Ting; Wang, Yi-Fu; Tzeng, Yi-Shiuan; Cui, Lu; Lai, Yun-Ju; Huang, Hsiang-Chi; Huang, Jia-Hsin; Ni, Hung-Chih; Tsai, Dong-Yan; Liang, Jian-Jong; Liao, Chun-Che; Lu, Ya-Ting; Jiang, Laurence; Liu, Ming-Tsan; JANN-TAY WANG ; SUI-YUAN CHANG ; Chen, Chung-Yu; HSING-CHEN TSAI ; Chang, Yao-Ming; Wernig, Gerlinde; Li, Chia-Wei; Lin, Kuo-I; Lin, Yi-Ling; Tsai, Huai-Kuang; Huang, Yen-Tsung; Chen, Shih-Yu | The Journal of Clinical Investigation | 28 | 21 | |
2018 | NK cell-derived IFN-γ protects against nontuberculous mycobacterial lung infection | HSIN-CHIH LAI ; Chang C.-J.; Lin C.-S.; Wu T.-R.; Hsu Y.-J.; Wu T.-S.; Lu J.-J.; Martel J.; Ojcius D.M.; Ku C.-L.; Young J.D.; Lu C.-C. | Journal of Immunology | 28 | 27 | |
2014 | NK cells kill mycobacteria directly by releasing perforin and granulysin | Lu C.-C.; Wu T.-S.; Hsu Y.-J.; Chang C.-J.; Lin C.-S.; Chia J.-H.; Wu T.-L.; Huang T.-T.; Martel J.; Ojcius D.M.; Young J.D.; HSIN-CHIH LAI | Journal of Leukocyte Biology | 90 | 81 | |